Feldman R G, Mosbach P A, Kelly M R, Thomas C A, Saint Hilaire M H
Ellen and Harold Wald Neurological Unit, University Hospital, Boston, MA.
Neurology. 1989 Nov;39(11 Suppl 2):96-101; discussion 105.
The combination of carbidopa and levodopa (Sinemet) is a highly effective treatment for the symptoms of Parkinson's disease. However, side effects, such as abnormal involuntary movements, fluctuations in motor performance, and "wearing off" phenomena limit its long-term usefulness in some patients. Open-label studies show that controlled-release Sinemet CR is effective in reducing motor fluctuations. This report discusses the results of a 14-week double-blind crossover study comparing the efficacy and tolerability of standard Sinemet with controlled-release Sinemet CR. Overall, there were no statistically significant differences in efficacy between Sinemet CR and standard Sinemet on any of the major efficacy measures, suggesting a clinical equivalence in terms of treating the symptoms of Parkinson's disease. The study also supports the tolerability of Sinemet CR. In summary, Sinemet CR holds the promise of reducing some disturbing side effects of long-term levodopa therapy, thus achieving optimal control of parkinsonian symptoms.
卡比多巴与左旋多巴的复方制剂（息宁）是治疗帕金森病症状的一种高效药物。然而，诸如异常不自主运动、运动功能波动以及“剂末”现象等副作用，在某些患者中限制了其长期应用价值。开放标签研究表明，控释息宁在减少运动波动方面有效。本报告讨论了一项为期14周的双盲交叉研究结果，该研究比较了标准息宁与控释息宁CR的疗效和耐受性。总体而言，在任何主要疗效指标上，息宁CR与标准息宁在疗效上均无统计学显著差异，这表明在治疗帕金森病症状方面具有临床等效性。该研究还支持了息宁CR的耐受性。总之，息宁CR有望减少长期左旋多巴治疗的一些令人困扰的副作用，从而实现对帕金森病症状的最佳控制。
